MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancerWenqing Qi, Daruka Mahadevan|BMC Cancer|2009Cited by 56